NCT06888232Completed
Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients
Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients: A Single Center Experience From South Punjab, Pakistan
Source: ClinicalTrials.gov · Last updated 21 Mar 2025
Brief summary (registry, in English)
This study aimed to determine the safety and efficacy of thalidomide in multi-transfused thalassemic children.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 121 (actual)
- First submitted
- 15 Mar 2025
- Start date
- 1 Aug 2023
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Muhammad Aamir Latif
- Diseases
- Thalassaemia
- NCT number
- NCT06888232
What you commit to
- Study type: Interventional
- Participants enrolled: 121
- From 1 Aug 2023 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Children with uncontrolled infections
- Malignancy
Other
- Significant hepatic or renal dysfunction
- Known contraindications to thalidomide
Who the study is looking for
- Children of both genders
- Aged 2-5 years
- With transfusion-dependent thalassemia (TDT)
- Whose parents/guardians showed willingness to adhere to follow-up visits
Age in the registry: 2 years to 5 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Children's Hospital & Institute of Child Health Coordinator of this site? Confirm its status | Multan | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.